The Risk of Risk Management
This article was originally published in RPM Report
Executive Summary
Risk management plans are an increasingly common feature of new drug approvals, and Congress seems set on making them a standard part of the FDA review process. Industry seems willing to go along, accepting some more restricitions on new products in exchange for restoring confidence in drug safety. There is only one problem: FDA is not so sure this is a great idea.
You may also be interested in...
Waking Up to REMS (Part 1): Don't Believe the Lack of Hype
FDA's top management can't be accused of overstating the importance of the agency's new drug safety tools. But sponsors need to wake up to the reality: the REMS are a critical fact of drug development and marketing.
FDA and Health Care Reform: An Activist Agenda for the Agency
Everyone is gearing up for a debate over health care reform in 2009-including the Food & Drug Administration. The regulator's role may be bigger than you think.
FDA and Health Care Reform: An Activist Agenda for the Agency
Everyone is gearing up for a debate over health care reform in 2009-including the Food & Drug Administration. The regulator's role may be bigger than you think.